Source: Pharmacy Times articles
Sundar Jagannath, MD, MBBS, discusses how linvoseltamab’s streamlined step-up dosing and REMS program support broader use in community settings and improved tolerability for older patients.
Recent Content
- Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT
- Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
- Expert: Linvoseltamab’s Simplified Dosing Expands Access, Enhances Tolerability in Multiple Myeloma
- Patient Perspective: Navigating Multiple Myeloma Treatment
- LAMP5 modulates IRF4 stability and nuclear transport: a critical mechanism in myeloma progression and therapy
- High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease
- Value of Spectral CT Techniques for the Assessment of Bone Marrow Infiltration in Multiple Myeloma: A Systematic Literature Review
- EHA 2025: Early Data Support Tocilizumab Use to Enable Outpatient Talquetamab Dosing in R/R Multiple Myeloma
- VIDEO: Four drugs ‘appear to be better’ in treatment of newly diagnosed multiple myeloma
- VIDEO: Cilta-cel may offer ‘cure’ in relapsed, refractory multiple myeloma